vorasidenib
agios pharma,servier
['vorasidenib', 'servier', '$agio', 'agiospharma']
two years ago, paid $1.8b to buy the #cancer portfolio, including #vorasidenib, a brain-penetrating drug candidate for a type of #braincancer. phase 3 data were announced . servier says it will seek fda approval. #asco2023 $agio
Business journalist based in #RTP, covering pharma and biotech (almost) everywhere. 71% free throw shooter. Genesis: Album 9, track 11.